Shanghai Leaderna Biomedical Technology Co., Ltd. (hereinafter “Leaderna Bio”) recently announced the completion of a Pre‑A financing round. This round was led by YuanSheng Venture Capital, with additional investment from Zhangke Lingyi. The funds raised will be primarily used to advance Leaderna Bio’s first PROTAC pipeline for autoimmune disease treatment into the clinical research stage, as well as to develop subsequent projects and pipelines targeting cancer and other autoimmune diseases.

Leaderna Bio was founded in September 2019 in Zhangjiang Science City by Dr. Yan Feng. The company’s R&D focus is on the development of targeted protein degradation therapeutics, concentrating on disease areas such as autoimmunity and oncology to address unmet clinical needs.

Beijing Caihe Law Firm conducted Freedom‑to‑Operate (FTO) due diligence for patent infringement risks in this financing round.